Soluble transforming growth factor β type II receptor attenuates TGF-β1 activity in human colorectal cancer LoVo cells

Several lines of evidence Support an important role of TGF-beta in the development of colorectal cancer, although the molecular consequences are Jargely unknown. Soluble transforming growth factor-beta receptor type II (sT beta RII) is a target of transforming growth factors-beta (TGF-beta) that plays an important role in regulation tumorigenesis, angiogenesis' and metastasis of cancer. To elucidate whether overexpression of sT beta RII could antagonize TGF-beta in colon cancer cells, we constructed a plasmid that contains a cDNA encoding human extracellular region of T beta RII and transfected this construction into LoVo cells. Surprisingly, in the absence of TGF-beta 1, the overexpression of sT beta RII antagonized TGF-beta-induced cell proliferation, invasion, motility and angiogenesis, and decreased expression of VEGF and MMP-9. Also, sT beta RII inhibited TGF-beta-induced apoptosis and improved the induction of antitumor immunity. Out data indicated that sT beta RII attenuated the biological activities of TGF-beta, suggesting that sT beta RII may have a therapeutic benefit in colorectal cancer.